129 related articles for article (PubMed ID: 8789722)
1. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells.
Cabantchik ZI; Glickstein H; Milgram P; Breuer W
Anal Biochem; 1996 Jan; 233(2):221-7. PubMed ID: 8789722
[TBL] [Abstract][Full Text] [Related]
2. Determination of the chelatable iron pool of isolated rat hepatocytes by digital fluorescence microscopy using the fluorescent probe, phen green SK.
Petrat F; Rauen U; de Groot H
Hepatology; 1999 Apr; 29(4):1171-9. PubMed ID: 10094962
[TBL] [Abstract][Full Text] [Related]
3. Chelation and mobilization of cellular iron by different classes of chelators.
Zanninelli G; Glickstein H; Breuer W; Milgram P; Brissot P; Hider RC; Konijn AM; Libman J; Shanzer A; Cabantchik ZI
Mol Pharmacol; 1997 May; 51(5):842-52. PubMed ID: 9145923
[TBL] [Abstract][Full Text] [Related]
4. Determination of the chelatable iron pool of single intact cells by laser scanning microscopy.
Petrat F; de Groot H; Rauen U
Arch Biochem Biophys; 2000 Apr; 376(1):74-81. PubMed ID: 10729192
[TBL] [Abstract][Full Text] [Related]
5. A review of fluorescence methods for assessing labile iron in cells and biological fluids.
Espósito BP; Epsztejn S; Breuer W; Cabantchik ZI
Anal Biochem; 2002 May; 304(1):1-18. PubMed ID: 11969183
[TBL] [Abstract][Full Text] [Related]
6. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II).
Breuer W; Epsztejn S; Cabantchik ZI
J Biol Chem; 1995 Oct; 270(41):24209-15. PubMed ID: 7592626
[TBL] [Abstract][Full Text] [Related]
7. Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes.
Ma Y; de Groot H; Liu Z; Hider RC; Petrat F
Biochem J; 2006 Apr; 395(1):49-55. PubMed ID: 16336208
[TBL] [Abstract][Full Text] [Related]
8. The chelatable iron pool in living cells: a methodically defined quantity.
Petrat F; de Groot H; Sustmann R; Rauen U
Biol Chem; 2002; 383(3-4):489-502. PubMed ID: 12033438
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and properties of novel iron(III)-specific fluorescent probes.
Luo W; Ma YM; Quinn PJ; Hider RC; Liu ZD
J Pharm Pharmacol; 2004 Apr; 56(4):529-36. PubMed ID: 15099448
[TBL] [Abstract][Full Text] [Related]
10. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
11. Ferric and cupric reductase activities by iron-limited cells of the green alga Chlorella kessleri: quantification via oxygen electrode.
Weger HG; Walker CN; Fink MB
Physiol Plant; 2007 Oct; 131(2):322-31. PubMed ID: 18251903
[TBL] [Abstract][Full Text] [Related]
12. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
Zhao R; Planalp RP; Ma R; Greene BT; Jones BT; Brechbiel MW; Torti FM; Torti SV
Biochem Pharmacol; 2004 May; 67(9):1677-88. PubMed ID: 15081867
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
[TBL] [Abstract][Full Text] [Related]
14. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
Bernhardt PV; Chin P; Richardson DR
J Biol Inorg Chem; 2001 Oct; 6(8):801-9. PubMed ID: 11713687
[TBL] [Abstract][Full Text] [Related]
15. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
16. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence analysis of the labile iron pool of mammalian cells.
Epsztejn S; Kakhlon O; Glickstein H; Breuer W; Cabantchik I
Anal Biochem; 1997 May; 248(1):31-40. PubMed ID: 9177722
[TBL] [Abstract][Full Text] [Related]
18. Does the calcein-AM method assay the total cellular 'labile iron pool' or only a fraction of it?
Tenopoulou M; Kurz T; Doulias PT; Galaris D; Brunk UT
Biochem J; 2007 Apr; 403(2):261-6. PubMed ID: 17233627
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals.
Dehne N; Lautermann J; Petrat F; Rauen U; de Groot H
Toxicol Appl Pharmacol; 2001 Jul; 174(1):27-34. PubMed ID: 11437646
[TBL] [Abstract][Full Text] [Related]
20. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
